PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Average Rating of “Moderate Buy” by Brokerages

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has received a consensus rating of “Moderate Buy” from the thirteen analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, nine have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $53.40.

A number of research firms recently weighed in on PRCT. Morgan Stanley lowered their price target on shares of PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 2nd. Leerink Partners restated an “outperform” rating and set a $55.00 target price on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Wednesday, October 8th. TD Cowen lowered their price objective on PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Finally, Jefferies Financial Group upgraded PROCEPT BioRobotics from a “hold” rating to a “strong-buy” rating in a report on Friday, December 12th.

Institutional Investors Weigh In On PROCEPT BioRobotics

Several hedge funds and other institutional investors have recently bought and sold shares of PRCT. Nuveen LLC acquired a new position in PROCEPT BioRobotics in the 1st quarter valued at about $11,302,000. Russell Investments Group Ltd. lifted its holdings in PROCEPT BioRobotics by 124,755.6% in the first quarter. Russell Investments Group Ltd. now owns 44,948 shares of the company’s stock valued at $2,619,000 after acquiring an additional 44,912 shares during the last quarter. Algert Global LLC grew its position in PROCEPT BioRobotics by 110.9% in the first quarter. Algert Global LLC now owns 50,288 shares of the company’s stock worth $2,930,000 after acquiring an additional 26,440 shares during the period. Hsbc Holdings PLC increased its stake in PROCEPT BioRobotics by 14.2% during the first quarter. Hsbc Holdings PLC now owns 163,044 shares of the company’s stock worth $9,499,000 after acquiring an additional 20,234 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new stake in PROCEPT BioRobotics during the first quarter worth $40,000. 89.46% of the stock is currently owned by institutional investors and hedge funds.

PROCEPT BioRobotics Stock Performance

NASDAQ PRCT opened at $32.73 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20. The stock’s 50 day simple moving average is $32.99 and its 200-day simple moving average is $42.94. The company has a market cap of $1.83 billion, a PE ratio of -21.39 and a beta of 0.99. PROCEPT BioRobotics has a 1-year low of $27.80 and a 1-year high of $89.49.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.03. PROCEPT BioRobotics had a negative return on equity of 21.72% and a negative net margin of 28.20%.The firm had revenue of $83.33 million during the quarter, compared to the consensus estimate of $80.78 million. During the same period in the prior year, the company earned ($0.40) EPS. The firm’s revenue was up 42.6% compared to the same quarter last year. As a group, equities research analysts anticipate that PROCEPT BioRobotics will post -1.75 EPS for the current fiscal year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).